US 11,655,306 B2
NK cell-activating fusion protein, NK cell, and pharmaceutical composition including same
Seok Ho Kim, Daejeon (KR); Jaemin Lee, Daejeon (KR); and Duck Cho, Seoul (KR)
Assigned to Korea Research Institute of Bioscience and Biotechnology
Appl. No. 16/500,051
Filed by KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY, Daejeon (KR)
PCT Filed Apr. 5, 2018, PCT No. PCT/KR2018/004043
§ 371(c)(1), (2) Date Oct. 1, 2019,
PCT Pub. No. WO2018/186706, PCT Pub. Date Oct. 11, 2018.
Claims priority of application No. 10-2017-0043988 (KR), filed on Apr. 5, 2017.
Prior Publication US 2020/0148786 A1, May 14, 2020
Int. Cl. C07K 16/32 (2006.01); A61P 35/00 (2006.01); A61K 9/00 (2006.01); C07K 14/52 (2006.01); C07K 16/28 (2006.01); A61K 39/00 (2006.01)
CPC C07K 16/32 (2013.01) [A61K 9/0019 (2013.01); A61P 35/00 (2018.01); C07K 14/521 (2013.01); C07K 16/2827 (2013.01); A61K 2039/505 (2013.01); C07K 2317/622 (2013.01); C07K 2317/732 (2013.01); C07K 2319/30 (2013.01)] 13 Claims
 
1. A fusion polypeptide, consisting of:
an antibody or fragment thereof that binds to a tumor-associated antigen;
a linker comprising a furin cleavage site; and
a natural killer (NK) cell-inducing protein of CXCL16,
wherein the CXCL16 consists of the amino acid sequence of SEQ ID NO: 17.